Investor relations

Our Shareholders

Merlin Biosciences

Merlin Biosciences Limited is a specialised venture investor in life sciences companies managing three funds, Merlin Fund (Fund I), Merlin Biosciences Fund (Fund II) and Merlin Biosciences Fund III (Fund III), worth in excess of €450 million of equity capital. Merlin invests in companies that are bringing to market human medicines or medical devices with groundbreaking technology and significant commercial potential.
Merlin Biosciences is part of the Excalibur Group an international integrated fund management and corporate finance business specialising in the medical sciences sector

Nexus Medical Partners

Nexus Medical Partners is a private equity firm, headquartered in Boston, MA, specializing in making private equity investments in and providing strategic assistance to medical technology and selected life science companies.

Kreos Capital

Kreos Capital, previously known as European Venture Partners (EVP), is Europe’s largest and leading venture debt provider. As the first dedicated venture debt provider in Europe in 1998, Kreos has adapted the experience of the US venture debt model to the European market. Since then, venture debt has become established as a complementary financing tool for venture-backed companies in Europe and Israel.

Rowan Dartington

Rowan Dartington is the South West’s leading stockbroker with approximately £1 billion under management. It is investing into Lab 21 via the Isambard Fund, their pre-IPO fund specializing in Renewable Energy, Biotechnology, Pharmaceutical and Engineering sectors. Jonathan Beatson-Hird, Managing Director of Rowan Dartington and also the fund manager for the Isambard Fund, said: Our strategy has been to build our investment portfolio around three sectors, one of which is the In vitro diagnostics market. This is a dynamic industry displaying strong defensive characteristics. We are delighted to be able to invest in Lab 21 which is a core holding for us. We believe that the current economic environment is ideal for the corporate strategy of consolidation and with their state of the art products and services makes the company well positioned for growth in these uncertain times.

Medicis

Medicis Capital is specialised on managing private equity investments and provides services in corporate finance, mergers & aquisitions and business development in the field of Healthcare. Focus Areas are the Pharmaceutical Industry, Medtech Industry and Healthcare Services including Care Delivery Facilities.